Esketamine
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Esketamine and local guidelines before prescribing.
NMDA antagonist
Mechanism
NMDA receptor antagonist nasal spray.
Uses
Treatment-resistant depression (specialist).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Dissociation, hypertension, nausea, dizziness.
Interactions
CNS depressants.
Contraindications and cautions
Uncontrolled hypertension, aneurysm
Monitoring
BP
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Caution in hepatic impairment
Overdose and reversal
Supportive
Special advice
Supervised administration with 2-hour observation.
More from the textbook: uses, cautions and other points
- Esketamine nasal spray - licensed for treatment-resistant depression but not recommended by NICE; ketamine used in some specialist services.
Psychiatry: assessment, treatment and the law - Esketamine (nasal) | Licensed for treatment-resistant depression; not recommended by NICE.
Psychiatry: assessment, treatment and the law - rTMS ; esketamine (not NICE-recommended); MAOIs (specialist).
Psychiatry: Mood disorders
Where it is discussed in the book
- Psychiatry: assessment, treatment and the law (2 mentions)
- Psychiatry: Mood disorders (1 mention)